Payment overview · 2025
General Payments
$915.50
56 reported records · 14 companies
Healthcare provider profile · identity verified
Kurtis A Woolf, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAYTON, UT · NPI 1528140878
Verified facts
What the public records show
CMS Open Payments records show Kurtis A Woolf, M.D. received $915.50 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.01 | 33.3% | 25 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $130.35 | 14.2% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $120.31 | 13.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.99 | 10.1% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.90 | 5.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.42 | 4.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.53 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.95 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.27 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.90 | 2.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.48 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.87 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.70 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.82 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $915.50 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $153.34 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $130.35 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $120.31 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.33 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $91.99 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.74 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.90 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 394 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 113 |
| Lisinopril | Lisinopril | 390 | 112 |
| Losartan Potassium | Losartan Potassium | 294 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 64 |
| Omeprazole | Omeprazole | 237 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 45 |
| Trazodone Hcl | Trazodone Hcl | 155 | 43 |
| Metformin Hcl Er | Metformin Hcl | 152 | 44 |
| Gabapentin | Gabapentin | 151 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 49 |
| Potassium Chloride | Potassium Chloride | 131 | 43 |
| Chlorthalidone | Chlorthalidone | 130 | 50 |
| Carvedilol | Carvedilol | 125 | 39 |
| Meloxicam | Meloxicam | 115 | 43 |
| Metformin Hcl | Metformin Hcl | 114 | 42 |
| Furosemide | Furosemide | 110 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 33 |
| Simvastatin | Simvastatin | 98 | 28 |
| Farxiga | Dapagliflozin Propanediol | 95 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 28 |
| Tramadol Hcl | Tramadol Hcl | 88 | 42 |
| Spironolactone | Spironolactone | 87 | 21 |
| Bupropion Xl | Bupropion Hcl | 86 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 24 |
| Alendronate Sodium | Alendronate Sodium | 77 | 25 |
| Alprazolam | Alprazolam | 74 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 42 |
| Sertraline Hcl | Sertraline Hcl | 71 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 60 |
| Trulicity | Dulaglutide | 64 | 15 |
| Glimepiride | Glimepiride | 61 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 18 |
| Allopurinol | Allopurinol | 54 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 50 | 13 |
| Eliquis | Apixaban | 49 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 13 |
| Xarelto | Rivaroxaban | 48 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Famotidine | Famotidine | 47 | 15 |
| Finasteride | Finasteride | 46 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 15 |
| Ozempic | Semaglutide | 45 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 16 |
| Valsartan | Valsartan | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 12 |
| Prednisone | Prednisone | 32 | 24 |
| Montelukast Sodium | Montelukast Sodium | 31 | 12 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 22 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | 14 |
| Naproxen | Naproxen | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $915.50 · 56 records | ABBVIE INC. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Korlym, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error